Net Product Revenue was BridgeBio Pharma’s largest product and service line in fiscal 2025, bringing in $362.40M of $502.11M (72%).
| Product and Service | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Net Product Revenue | — | $2.90M | $362.40M | ||
| License & Services Revenue | $9.30M | $218.85M | $128.32M | ||
| License Revenue | — | — | — | ||
| Royalty Revenue | — | $169.00K | $11.39M | ||
| Total | $9.30M | $221.92M | $502.11M |
BridgeBio Pharma brought in $502.11M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 126.3% from $221.92M in fiscal 2024. Net Product Revenue was the largest at $362.40M (72.2%), ahead of License & Services Revenue at $128.32M (25.6%) and Royalty Revenue at $11.39M (2.3%).
Compared with fiscal 2024, Net Product Revenue grew fastest, up 12,396.6% to $362.40M, while License & Services Revenue fell the most, down 41.4% to $128.32M.
BridgeBio Pharma began breaking out Net Product Revenue in fiscal 2024 and Royalty Revenue in fiscal 2024.
Bayer was BridgeBio Pharma’s largest revenue line in fiscal 2024, bringing in $131.50M of $218.20M (60%).
| Counterparty Name | FY 2024 |
|---|---|
| Bayer | $131.50M |
| Kyowa Kirin Co., Ltd | $76.20M |
| Bms | $9.90M |
| Alexion License Agreements | $600.00K |
| Total | $218.20M |
BridgeBio Pharma brought in $218.20M from its four revenue lines in fiscal 2024, the year ended December 31, 2024. Bayer was the largest at $131.50M (60.3%), ahead of Kyowa Kirin Co., Ltd at $76.20M (34.9%) and Bms at $9.90M (4.5%). The remaining revenue line, Alexion License Agreements, brought in $600.00K.
BridgeBio Pharma (BBIO) reports its revenue by product and service and by counterparty name. In fiscal 2025, Net Product Revenue was its largest product and service line, bringing in $362.40M (72.2% of the total), followed by License & Services Revenue at $128.32M (25.6%).
Net Product Revenue was BridgeBio Pharma's largest product and service line in fiscal 2025, bringing in $362.40M, or 72.2% of the $502.11M total across its three product and service lines.
Bayer was BridgeBio Pharma's largest revenue line in fiscal 2024, bringing in $131.50M, or 60.3% of the $218.20M total across its four revenue lines.
Among BridgeBio Pharma's product and service lines that make up at least 2% of revenue, Net Product Revenue grew fastest in fiscal 2025, up 12,396.6% from $2.90M to $362.40M.
Every figure comes from BridgeBio Pharma's annual financial filings, as reported. Each line keeps the name BridgeBio Pharma gives it, and years follow its fiscal calendar.
BridgeBio Pharma's revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.